A Study of Modafinil for the Treatment of Fatigue in Patients with Primary Biliary Cirrhosis

Overview

Información sobre este estudio

The purpose of this study is to evaluate the safety and effectiveness of modafinil for the treatment of fatigue in patients who have Primary Biliary Cirrhosis.

 

Elegibilidad para la participación

Los requisitos de elegibilidad de los participantes incluyen la edad, el sexo, el tipo y el estadio de la enfermedad, y los problemas de salud o tratamientos previos. Las pautas difieren de un estudio a otro e identifican quiénes pueden o no pueden participar. No hay garantía de que cada persona elegible que desee participar en un ensayo se inscribirá. Comunícate con el equipo del estudio para analizar la elegibilidad del estudio y la posible participación.

Inclusion Criteria

  • Primary biliary cirrhosis will be defined as present when 2 of 3 of the following criteria are met
    • Chronic cholestatic liver disease for greater than 6 months with alkaline phosphatase levels greater than 1.5 times the upper limit of normal prior to UDCA treatment
    • Positive AMA titer greater or equal to 1:40 or AMA greater than 0.1U
    • Liver histology in the past with features consistent with or diagnostic of PBC
  • A previous ultrasound, computed tomography (CT), or cholangiography of the biliary tree excludes biliary obstruction
  • Verbal report of fatigue for greater than 6 months

Exclusion Criteria

  • Other serious coexistent conditions such as pre-existing advanced malignancy or severe cardiopulmonary disease which would be expected to limit life expectancy to less than three years
  • Findings highly suggestive of liver disease of other etiology such as chronic alcoholic liver disease, chronic hepatitis B or C infection, hemochromatosis, Wilson's disease, 1-antitrypsin deficiency, non-alcoholic steatohepatitis or sclerosing cholangitis
  • Treatment of underlying PBC has been modified in the preceding six months
  • Anticipated need for transplantation in one year (Mayo survival model < 80% one-year survival without transplant) or MELD above 15
  • Recurrent variceal bleeding, presence of diuretic-resistant ascites, or spontaneous encephalopathy
  • Active drug or alcohol use
  • History of drug and/or stimulant (e.g. methylphenidate, amphetamine, or cocaine) abuse
  • Serum bilirubin >4 mg/dl
  • Serum creatinine over 1.4 mg/dl
  • Pregnancy
  • Breast-feeding
  • Inability or unwillingness to practice contraceptive measures for the prevention of pregnancy if appropriate
  • Other fatigue related diagnoses such as anemia, thyroid disease, renal failure, use of beta-blockers and untreated depression
  • Known hypersensitivity to modafinil
  • Uncontrolled hypertension
  • Hypertension and left ventricular hypertrophy documented on ECG in the last 2 years
  • Recent (< 6 months) history of myocardial infarction or unstable angina
  • history of psychosis
  • Receiving cyclosporine, warfarin, tricyclic agents, carbamazepine, phenobarbital, rifampin, ketoconazole or itraconazole in the last 3 months

Sedes participantes de Mayo Clinic

Los estatus de los estudios cambian con frecuencia. Comunícate con el equipo del estudio para obtener la información más actualizada acerca de la posibilidad de participar.

Sede de Mayo Clinic Estatus

Rochester, Minn.

Investigador principal de Mayo Clinic

Jayant Talwalkar, M.D.

Cerrado para la inscripción

More information

Publicaciones

Publications are currently not available
.
CLS-20311334

Mayo Clinic Footer